Prelude therapeutics announces closing of upsized public offering and full exercise of underwriters' option to purchase additional shares

Wilmington, del., jan. 11, 2021 (globe newswire) -- prelude therapeutics incorporated (“prelude” or “the company”) (nasdaq: prld), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters' option to purchase an additional 375,000 shares of its voting common stock. the aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by prelude.
PRLD Ratings Summary
PRLD Quant Ranking